Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2020 Aug 11

PMID 32774364

Citations 5

Authors

Cristina Antinozzi

Paolo Sgro

Luigi Di Luigi

Affiliations

Soon will be listed here.

Abstract

Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have long been used as an effective therapeutic option for the treatment of erectile dysfunction (ED). Different studies have demonstrated that PDE5i, by sensitizing insulin target tissues to insulin, play an important role in controlling the action of insulin and glucose metabolism, highlighting the protective action of these drugs against metabolic diseases. In this review, we report the latest knowledge about the role of PDE5i in the metabolic diseases of insulin resistance and type 2 diabetes, highlighting clinical aspects and potential treatment approaches. Although various encouraging data are available, further in vivo and in vitro studies are required to elucidate the mechanism of action and their clinical application in humans.

Citing Articles

Insulin Resistance, a Risk Factor for Alzheimer's Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach.

Affuso F, Micillo F, Fazio S Biomedicines. 2024; 12(8).

PMID: 39200352 PMC: 11351221. DOI: 10.3390/biomedicines12081888.

Hydrogen Peroxide Stimulates Dihydrotestosterone Release in C2C12 Myotubes: A New Perspective for Exercise-Related Muscle Steroidogenesis?.

Antinozzi C, Duranti G, Ceci R, Lista M, Sabatini S, Caporossi D Int J Mol Sci. 2022; 23(12).

PMID: 35743011 PMC: 9223901. DOI: 10.3390/ijms23126566.

Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts.

Antinozzi C, Sgro P, Marampon F, Caporossi D, Del Galdo F, Dimauro I Biology (Basel). 2021; 10(6).

PMID: 34073032 PMC: 8229934. DOI: 10.3390/biology10060491.

Research Trends in the Efficacy of Stem Cell Therapy for Hepatic Diseases Based on MicroRNA Profiling.

Kweon M, Kim J, Jun J, Kim G Int J Mol Sci. 2021; 22(1).

PMID: 33383629 PMC: 7795580. DOI: 10.3390/ijms22010239.

Role of Phosphodiesterase in the Biology and Pathology of Diabetes.

Kilanowska A, Ziolkowska A Int J Mol Sci. 2020; 21(21).

PMID: 33153226 PMC: 7662747. DOI: 10.3390/ijms21218244.

References

Liu V, Huang P . Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res. 2007; 77(1):19-29. PMC: 2731989. DOI: 10.1016/j.cardiores.2007.06.024. View

Giannattasio S, Corinaldesi C, Colletti M, Di Luigi L, Antinozzi C, Filardi T . The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence. J Endocrinol Invest. 2018; 42(6):715-725. PMC: 6531405. DOI: 10.1007/s40618-018-0977-y. View

Gowans G, Hawley S, Ross F, Grahame Hardie D . AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 2013; 18(4):556-66. PMC: 3791399. DOI: 10.1016/j.cmet.2013.08.019. View

Zhang X, Ji J, Yan G, Wu J, Sun X, Shen J . Sildenafil promotes adipogenesis through a PKG pathway. Biochem Biophys Res Commun. 2010; 396(4):1054-9. DOI: 10.1016/j.bbrc.2010.05.064. View

Aversa A, Fittipaldi S, Francomano D, Bimonte V, Greco E, Crescioli C . Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization. Endocrine. 2017; 56(3):639-648. DOI: 10.1007/s12020-016-1208-y. View

Yu H, Chung H, Kim K, Lee J, Hong J, Park K . PDE 5 inhibitor improves insulin sensitivity by enhancing mitochondrial function in adipocytes. Biochem Biophys Res Commun. 2017; 493(1):631-636. DOI: 10.1016/j.bbrc.2017.08.140. View

Hoffman E, VonWald T, Hansen K . The metabolic syndrome. S D Med. 2015; Spec No:24-8. View

Rotella D . Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov. 2002; 1(9):674-82. DOI: 10.1038/nrd893. View

Campolo F, Zevini A, Cardarelli S, Monaco L, Barbagallo F, Pellegrini M . Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line. J Cell Physiol. 2017; 233(1):325-337. DOI: 10.1002/jcp.25880. View

10.

Venneri M, Giannetta E, Panio G, De Gaetano R, Gianfrilli D, Pofi R . Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice. PLoS One. 2015; 10(5):e0126580. PMC: 4427327. DOI: 10.1371/journal.pone.0126580. View

11.

Lira V, Soltow Q, Long J, Betters J, Sellman J, Criswell D . Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab. 2007; 293(4):E1062-8. DOI: 10.1152/ajpendo.00045.2007. View

12.

Hsueh W, Lyon C, Quinones M . Insulin resistance and the endothelium. Am J Med. 2004; 117(2):109-17. DOI: 10.1016/j.amjmed.2004.02.042. View

13.

Deshmukh A, Long Y, de Castro Barbosa T, Karlsson H, Glund S, Zavadoski W . Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)alpha1-specific activity and glucose transport in human skeletal muscle. Diabetologia. 2010; 53(6):1142-50. PMC: 2860569. DOI: 10.1007/s00125-010-1716-x. View

14.

Ryu S, Choi Y, Park S, Kim J, Kim Y, Kim Y . Udenafil, a Phosphodiesterase 5 Inhibitor, Reduces Body Weight in High-Fat-Fed Mice. World J Mens Health. 2017; 36(1):41-49. PMC: 5756806. DOI: 10.5534/wjmh.17028. View

15.

Roberts J, Booth L, Conley A, Cruickshanks N, Malkin M, Kukreja R . PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther. 2014; 15(6):758-67. PMC: 4049791. DOI: 10.4161/cbt.28553. View

16.

Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, Di Dato C . PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. J Clin Endocrinol Metab. 2016; 101(4):1525-34. DOI: 10.1210/jc.2015-4252. View

17.

Sandner P, Hutter J, Tinel H, Ziegelbauer K, Bischoff E . PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res. 2007; 19(6):533-43. DOI: 10.1038/sj.ijir.3901577. View

18.

Hamilton T, Hu N, Kolomitro K, Bell E, Maurice D, Graham C . Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. World J Urol. 2012; 31(2):325-30. DOI: 10.1007/s00345-012-0848-7. View

19.

Kukreja R, Salloum F, Das A, Koka S, Ockaili R, Xi L . Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol. 2011; 16(4):e30-5. PMC: 3206106. View

20.

Deedwania P . Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. Cardiol Clin. 2004; 22(4):505-9, v. DOI: 10.1016/j.ccl.2004.07.001. View